Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more

Recent & Breaking News (NDAQ:VTVT)

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2024

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

GlobeNewswire July 26, 2024

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

GlobeNewswire June 24, 2024

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

PR Newswire May 28, 2024

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2024

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

PR Newswire March 19, 2024

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

GlobeNewswire March 13, 2024

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

GlobeNewswire March 4, 2024

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire March 1, 2024

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

GlobeNewswire February 28, 2024

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

PR Newswire February 22, 2024

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

GlobeNewswire November 8, 2023

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

GlobeNewswire November 2, 2023

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

GlobeNewswire November 1, 2023

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

PR Newswire September 27, 2023

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

PR Newswire September 26, 2023

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

PR Newswire September 18, 2023

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2023